CureVac B.V

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The Boston-based fund has emerged as a force to be reckoned with in the world of biotech investments.

Peter Kolchinsky-led RA Capital's New Positions Feature CureVac, Mineralys, Pilant, Enliven Therapeu

CureVac NV said on Friday it had filed an expanded patent infringement claim against Pfizer Inc and BioNTech over the use of mRNA technology and that a U.S. court had granted its request to transfer the trial.

CureVac files expanded patent lawsuit against Pfizer/BioNTech over mRNA technology

Motion to transfer U.S. litigation to Eastern District of Virginia granted at CureVac's request and expected to significantly accelerate U.S. litigation timeline CureVac is filing counterclaim in U.S. court under nine patents covering foundational mRNA innovations highly relevant to the design, formulation and manufacturing of Comirnaty® German Federal Patent Court issued preliminary opinion in April 2023 supporting validity of a German patent corresponding to one of the patents enforced against Pfizer/BioNTech in the U.S. TÜBINGEN, GERMANY / ACCESSWIRE / May 19, 2023 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that its motion to transfer the ongoing patent litigation filed by Pfizer/BioNTech in the federal district court of Massachusetts has been granted, moving the case to the Eastern District of Virginia.

CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech

Initial Phase 1 part started with multivalent modified mRNA influenza vaccine candidates Candidates developed in collaboration with GSK within broad infectious disease vaccine program encode for antigens covering four WHO-recommended flu strains TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / May 8, 2023 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that the first participant was dosed in the Phase 1 part of a combined Phase 1/2 study of multivalent, modified mRNA seasonal flu vaccine candidates, developed in collaboration with GSK.

CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK

CureVac N.V. (CVAC) Q4 2022 Earnings Call Transcript.

CureVac N.V. (CVAC) Q4 2022 Earnings Call Transcript

CureVac: Potential Of mRNA Tech Beyond Covid-19 Vaccine Development.

CureVac: Potential Of mRNA Tech Beyond Covid-19 Vaccine Development

In 2022, ongoing business transformation driven by COVID-19 and flu clinical develop­ments in collaboration with GSK and successful broadening of oncology footprint Early 2023, strong validation of CureVac's proprietary mRNA technology platform from positive preliminary Phase 1 data in COVID-19 and flu in collaboration with GSK Monovalent modified COVID-19 candidate CV0501 demonstrated efficient booster activity and good tolerability across now available dose range of 3 to 200µg Monovalent modified flu candidate Flu-SV-mRNA showed immunogenicity in line with licensed comparator at lowest dose of 2µg; strong performance in older adults Modified mRNA technology selected as preferred technology; on track with new clinical studies in flu and COVID-19 in Q2 and later in 2023, with updated candidates On track with first proof-of-principle study in Q2 2023 for clinical validation of second-generation mRNA backbone in oncology Progressing proprietary LNP development programs for optimized and targeted mRNA delivery in prophylactic vaccines as well as cancer vaccines Cash and cash equivalents position of €495.8 million as of December 31, 2022 $250 million in gross proceeds raised with issuance of 27,027,028 common shares in February 2023 extend cash reach to mid-2025 TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 25, 2023 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced financial results for the fourth quarter and full-year 2022 and provided a business update.

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 18, 2023 / CureVac N.V. (Nasdaq:CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the fourth quarter and full-year 2022 on Tuesday, April 25, 2023.

CureVac to Report Fourth Quarter and Full-Year 2022 Financial Results and Business Updates on April 25, 2023

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / March 28, 2023 / CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the voting results of the Company's extraordinary general meeting.

CureVac Announces Voting Results of Extraordinary General Meeting

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / February 10, 2023 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), announced today the closing of its follow-on public offering of 27,027,028 common shares, at a public offering price of $9.25 per common share, for total gross proceeds of approximately $250 million before deducting underwriting discounts and commissions and offering expenses payable by CureVac.

CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares

TÜBINGEN, GERMANY / BOSTON, MA / ACCESSWIRE / February 7, 2023 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), announced today that it intends to offer $200 million of its common shares in an underwritten public offering.

CureVac Announces Proposed Public Offering of Common Shares

Dr. Mendila joins CureVac as Chief Development Officer with more than 20 years of global industry experience TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / February 1, 2023 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that Myriam Mendila has taken up her role as CureVac's Chief Development Officer, as previously announced.

CureVac Welcomes Myriam Mendila as New Chief Development Officer

CureVac recognized as a Top 100 innovator in acknowledgment of the company's innovative strength and extensive intellectual property portfolio The company holds one of broadest intellectual property portfolios in mRNA technology TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / January 31, 2023 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced its inclusion in the second annual "Innovation Momentum: The Global Top 100" report by LexisNexis®.

CureVac Named as One of the World's Most Dynamic Innovators by LexisNexis(R)

Continued technology platform validation with extended preliminary data from older adults in ongoing Phase 1 studies in COVID-19 and flu COVID-19: monovalent modified mRNA construct CV0501 successfully boosted antibody titers against BA.1 and ancestral variants in adults age ≥65 Flu: monovalent modified mRNA construct Flu-SV-mRNA elicited antibodies approximately 2.3 times those of licensed vaccine comparator in adults aged 60-80 Reaffirming plan to advance modified mRNA COVID-19 and flu candidates to the next stages of clinical development in collaboration with GSK in 2023 TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / January 30, 2023 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced positive extended preliminary data from ongoing Phase 1 clinical programs in COVID-19 and seasonal flu conducted in collaboration with GSK.

CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs

CureVac's CVAC, +8.44% promising Phase 1 data for flu and COVID-19 vaccine candidates is a signal to investors that its messenger RNA technology is, in fact, competitive, according to UBS Securities analysts, who upgraded the company's stock to Buy from Neutral on Thursday. They also raised the price target to $18 from $8.

UBS: CureVac has a ‘potentially competitive mRNA platform'

Shares of CureVac BV (NASDAQ: CVAC) have already almost doubled year-to-date but a UBS analyst says the stock still has a lot more room to the upside.

UBS reveals a biotech stock that can nearly double from here

AbbVie

CRISPR Therapeutics

Exelixis

Incyte

Pfizer

Sarepta Therapeutics

If you have the patience to go through wild undulations, then you may be a candidate for biotech stocks that will make you rich in 10 years. Even among the most established biotechnology firms, they're seemingly one news item away from disaster.

7 Biotech Stocks That Will Make You Rich in 10 Years

The stock rose for the third consecutive day.

Why CureVac's Shares Jumped on Tuesday

Moderna

Ocugen, Inc.

A flurry of announcements relating to COVID vaccines dominated headlines on the pandemic on Monday, with Moderna telling investors it expects to generate some $5 billion in sales in 2023.

Moderna, CureVac and Ocugen offer updates on COVID vaccines, while China cracks down on critics of government's pandemic response

Dr. Franz-Werner Haas to complete successful tenure as CEO by March 31, 2023 Dr. Alexander Zehnder to succeed Dr. Haas as new CEO, joining from Sanofi on April 1, 2023 TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / January 9, 2023 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that after more than 10 years as a member of the CureVac management board and three years as CEO, Dr. Franz Haas will step down as CEO, effective March 31, 2023.

CureVac Appoints Alexander Zehnder as CEO From April 1, 2023

CureVac CVAC, +29.47% shares rocketed 26% in premarket trade as the German company said preliminary data from its early stage trial for its COVID-19 and seasonal flu shots had positive results to advance to the next stage of clinical testing. CureVac is developing the shots with GlaxoSmithKline GSK, +1.28% GSK, -1.38%.

CureVac shares surge after preliminary data on COVID-19 and flu shots

Amid a strong showing on Wall Street prior to the weekend, shares of CureVac (NASDAQ: CVAC ) stock popped dramatically northward on positive data for its coronavirus and flu vaccines. Preliminary clinical results demonstrate effectiveness against the omicron variant of Covid-19 along with the seasonal flu.

CureVac (CVAC) Stock Rises 25% on Positive Data for Covid-19 and Flu Vaccines

Promising COVID-19 and flu modified mRNA vaccine candidates identified based on positive preliminary data from ongoing Phase 1 studies All candidates use CureVac's advanced second-generation mRNA backbone optimized to achieve improved mRNA translation and strong immune responses at low doses The preliminary results provide strong evidence of technology for CureVac's mRNA platform; CureVac and partner GSK plan to advance modified mRNA COVID-19 and flu candidates to the next stages of clinical development COVID-19: monovalent modified mRNA vaccine candidate CV0501, encoding Omicron variant BA.1, successfully boosted antibody titers against BA.1 and the wild type variants and was generally well tolerated across all tested dose groups Flu: monovalent modified mRNA vaccine candidate Flu-SV-mRNA successfully boosted antibody titers against matching flu strain; even at lowest dose, titers were at least in line with a licensed comparator; Flu-SV-mRNA was well tolerated across all tested dose groups CureVac to host a webcast and conference call on January 6, 2023 at 3:00 p.m. CET / 9:00 a.m.

CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / December 14, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that Chief Executive Officer Franz-Werner Haas, Chief Financial Officer Pierre Kemula and Interim Chief Development Officer Ulrike Gnad-Vogt sold an aggregate of 103,775 CureVac common shares.

CureVac Members of Management Sell Shares to Cover Tax Obligations from Long Term Incentive Program

The consensus price target hints at a 139% upside potential for CureVac N.V. (CVAC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

News for CureVac B.V Stock (CVAC)